XML 53 R15.htm IDEA: XBRL DOCUMENT v3.8.0.1
Disaggregation of Revenues, Geographic Sales and Product Sales
3 Months Ended
Mar. 30, 2018
Segment Reporting [Abstract]  
Disaggregation of Revenues, Geographic Sales and Product Sales Disclosure [Text Block]
Note 9 — Disaggregation of Revenues, Geographic Sales and Product Sales
 
In the following tables, revenues are disaggregated by category, sales by geographic market and sales by product data. The following breaks down revenues into the following categories (in thousands):
 
 
 
Three Months Ended
 
 
 
March 30,
2018
 
March 31,
2017
 
Non-consignment sales
 
$
22,181
 
$
15,756
 
Consignment sales
 
 
4,912
 
 
4,594
 
Total net sales
 
 
27,093
 
 
20,350
 
Royalty income (1)
 
 
157
 
 
131
 
Total revenues
 
$
27,250
 
$
20,481
 
(1)
Shown as a separate line item in other income, net on the Condensed Consolidated Statements of Operations.
 
The Company markets and sells its products in over 75 countries and conducts its manufacturing in the United States. Other than China, Japan, the United States and Korea, the Company does not conduct business in any country in which its sales exceed 10% of worldwide consolidated net sales. Sales are attributed to countries based on location of customers. The composition of the Company’s net sales to unaffiliated customers is set forth below (in thousands):
 
 
 
Three Months Ended
 
 
 
March 30,
2018
 
March 31,
2017
 
China
 
$
7,910
 
$
4,626
 
Japan
 
 
5,083
 
 
3,799
 
Korea
 
 
2,195
 
 
1,426
 
United States
 
 
1,756
 
 
1,958
 
Other(1)
 
 
10,149
 
 
8,541
 
Total net sales
 
$
27,093
 
$
20,350
 
 
(1)       No other location individually exceeds 10% of the total sales.
 
100% of the Company’s sales are generated from the ophthalmic surgical product segment and the chief operating decision maker makes operating decisions and allocates resources based upon the consolidated operating results, and therefore the Company operates as one operating segment for financial reporting purposes. The Company’s principal products are implantable Collamer lenses (“ICLs”) used in refractive surgery and intraocular lenses (“IOLs”) used in cataract surgery. The composition of the Company’s net sales by product line is as follows (in thousands):
 
 
 
Three Months Ended
 
 
 
March 30,
2018
 
March 31,
2017
 
ICls
 
$
21,158
 
$
15,271
 
Other product sales
 
 
 
 
 
 
 
IOLs
 
 
4,058
 
 
4,606
 
Other surgical products
 
 
1,877
 
 
473
 
Total other product sales
 
 
5,935
 
 
5,079
 
Total net sales
 
$
27,093
 
$
20,350
 
 
One customer, our distributor in China, accounted for 29% and 23% of net sales for the three ended March 30, 2018 and March 31, 2017, respectively. As of March 30, 2018 and December 29, 2017, respectively, one customer, our distributor in China, accounted for 31% and 24% of consolidated trade receivables.